# Pharmacokinetics and Safety of Single-Dose Telbivudine in Children and Adolescents With Chronic Hepatitis B

> **NCT00907894** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 22 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** LDT600 (Telbivudine)

## Key facts

- **NCT ID:** NCT00907894
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2012-03
- **Final completion:** —
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00907894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00907894, "Pharmacokinetics and Safety of Single-Dose Telbivudine in Children and Adolescents With Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00907894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*